A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia

Preventive Medicine

Volumn 57, Issue 4, 2013, Pages 297-303

  Topp, Libby ^a   Day, Carolyn A ^b   Wand, Handan ^a   Deacon, Rachel M ^b   van Beek, Ingrid ^c   Haber, Paul S ^b,d   Shanahan, Marian ^e   Rodgers, Craig ^c   Maher, Lisa ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Kirketon Road Centre ^*  (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Conditional cash transfers; Contingency management; Hepatitis B; People who inject drugs; Vaccination

Indexed keywords

HEPATITIS B VACCINE;

ABORIGINE; ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; FEMALE; FIELD STUDY; FINANCIAL INCENTIVE; HEPATITIS B; HIGH RISK BEHAVIOR; HUMAN; HUMAN EXPERIMENT; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ABUSE; MALE; MASS IMMUNIZATION; MEDICATION COMPLIANCE; MISCELLANEOUS NAMED GROUPS; NORMAL HUMAN; PATIENT COMPLIANCE; PEOPLE WHO INJECT DRUGS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; REVACCINATION; REWARD; SELF REPORT;

CONDITIONAL CASH TRANSFERS; CONTINGENCY MANAGEMENT; HEPATITIS B; PEOPLE WHO INJECT DRUGS; VACCINATION;

ADULT; AUSTRALIA; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; MOTIVATION; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84883761415     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2013.04.013     Document Type: Article

References (42)

1. Achat H., Mclntyre P., Burgess M. Health care incentives in immunisation. Aust. N. Z. J. Public Health 1999, 23:285-288.
2. Amin J., Law M.G., Bartlett M., Kaldor J.M., Dore G.J. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006, 368:938-945.
3. Australian Government Department of Health and Ageing Australian Immunisation Handbook 2008, Australian Government Department of Health and Ageing, Canberra. 9th edition.
4. Campbell J.V., Garfein R.S., Thiede H., et al. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug user. Drug Alcohol Depend. 2007, 91S:S64-S72.
5. Day C., White B., Ross J., Dolan K. Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney (letter). Aust. N. Z. J. Public Health 2003, 27:558.
6. Day C.A., Islam M.M., White A., Reid S.E., Hayes S., Haber P.S. Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Aust. J. Prim. Health 2011, 17:10-15.
7. Deacon R., Topp L., Wand H., et al. Correlates of susceptibility to hepatitis B virus infection among people who inject drugs in Sydney, Australia. J. Urban Health 2012, 5.
8. Des Jarlais D.C., Paone D., Milliken J., et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999, 353:1657-1661.
9. Des Jarlais D.C., Fisher D.G., Newman J.C., et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am. J. Public Health 2001, 91:1791-1792.
10. Fattovich G. Natural Hisotry of hepatitis B. J. Hepatol. 2003, 39:S50-S58.
11. Gidding H.F., Warlow M., MacIntyre C.R., et al. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 2007, 25:8637-8641.
12. Gossop M., Griffiths P., Powis B., Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br. J. Addict. 1992, 87:1527-1536.
13. Harries A.D., Clark M., Beeching N.J., Lavelle J., Mutton K.J. Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J. Infect. 1991, 23:251-254.
14. Higgins S.T., Silverman K., Sigmon S.C., Naito N.C. Incentives and health: an introduction. Prev. Med. 2012, 55:S2-S6.
15. Hu Y., Grau L.E., Scott G., et al. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am. J. Prev. Med. 2008, 35:25-32.
16. Hwang L.-Y., Grimes C.Z., Tran T.Q., et al. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J. Infect. Dis. 2010, 202:1500-1509.
17. Islam M., Topp L., Conigrave K.M., et al. The reliability of sensitive information provided by injecting drug users in a clinical setting: clinician administered versus audio computer assisted self interviewing (ACASI). AIDS Care 2012, 24:1496-1503.
18. Islam M.M., Topp L., Day C.A., Dawson A., Conigrave K.M. The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. Int. J. Drug Policy 2012, 23:94-102.
19. Iversen J., Topp L., Maher L. Australian NSP Survey National Data Report 1995-2010 2011, The Kirby Institute for Infection and Immunity in Society, The University of New South Wales, Sydney.
20. Jilg W., Schmidt M., Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J. Infect. Dis. 1989, 160:766-769.
21. Lawrinson P., Copeland J., Indig D. Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy. Drug Alcohol Depend. 2005, 80:125-134.
22. Lugoboni F., Migliozzi S., Schiesari F., et al. Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine 1997, 15:1014-1016.
23. Lum P.J., Ochoa K.C., Hahn J.A., Page Shafer K., Evans J.L., Moss A.R. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO study. Am. J. Public Health 2003, 93:919-923.
24. MacDonald V., Dore G.J., Amin J., Van Beek I. Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary sexual health care facility. Sex. Health 2007, 4:27-30.
25. Marchou B., Picot N., Chavanet P., et al. Three-week hepatitis B vaccination provides protective immunity. Vaccine 1993, 11:1383-1385.
26. Marchou B., Excler J.L., Bourderioux C., et al. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J. Infect. Dis. 1995, 172:258-260.
27. Menzies R., McIntyre P. Vaccine preventable diseases and vaccination policy for indigenous populations. Epidemiol. Rev. 2006, 28:71-80.
28. National Centre in HIV Epidemiology and Clinical Research HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2011 2011, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney.
29. National Institutes of Health and Clinical Excellence Drug Misuse: Psychosocial Interventions 2007, National Institute for Health and Clinical Excellence, London.
30. Petry N.M. Contingency management treatments. Br. J. Psychiatry 2006, 189:97-98.
31. Ranganathan M., Lagarde M. Promoting healthy behaviours and improving health outcomes in low and middle income countries: a review of the impact of conditional cash transfer programmes. Prev. Med. 2012, 55:S95-S105.
32. Rodrigo J.M., Serra M.A., Aparisi L., et al. Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine 1992, 10:798-801.
33. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addiction 1993, 88:791-804.
34. Seal K.H., Kral A.H., Lorvick J., McNees A., Gee L., Edlin B.R. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis, B vaccine series among injection drug users. Drug Alcohol Depend. 2003, 71:127-131.
35. Stitzer M.L., Polk T., Bowles S., Kosten T. Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend. 2010, 107:76-79.
36. Tawk H.M., Vickery K., Bisset L., Selby W., Cossart Y.E. The impact of hepatitis B vaccination in a Western country: recall of vaccination and serological status in Australian adults. Vaccine 2006, 24:1095-1106.
37. Topp L., Day C.A., Dore G.J., Maher L. Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. Drug Alcohol Rev. 2009, 28:669-675.
38. Trubatch B.N., Fisher D.G., Cagle H.H., Fenaughty A.M. Vaccination strategies for targetted and difficult-to-access groups (letter). Am. J. Public Health 2000, 90:447.
39. Van Beek I. Case study: accessible primary health care-a foundation to improve health outcomes for people who inject drugs. Int. J. Drug Policy 2007, 18:329-332.
40. White B., Dore G.J., Lloyd A., Rawlinson W., Maher L. Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney. Aust. N. Z. J. Public Health 2012, 36:351-357.
41. World Health Organization Policy Brief: Guidance on Prevention of Viral Hepatitis B and C Among People Who Inject Drugs 2012, WHO, Geneva.
42. Wright N.M.J., Campbell T.L., Tompkins C.N.E. Comparison of conventional and accelerated hepatitis B immunization schedules for homeless drug users. Commun. Dis. Public Health 2002, 5:324-326.